Publications by authors named "S Leboulleux"
Background: ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [involvement of regional lymph nodes that cannot be assessed in the absence of neck dissection]), showed the non-inferiority of a follow-up strategy without radioactive iodine (I) administration compared with a postoperative I administration at 3 years post-randomisation. Here, we report a pre-specified analysis after 5 years of follow-up.
Methods: Patients treated with total thyroidectomy with or without prophylactic neck lymph node dissection, without postoperative suspicious findings on neck ultrasonography, were randomly assigned to the no-radioiodine group or to the radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone).
Purpose: Mitotane is the only approved treatment for metastatic adrenocortical carcinoma (ACC). Monitoring plasma levels is recommended, but its predictive value is insufficient.
Methods: This prospective study of the French ENDOCAN-COMETE network aimed to investigate the prognostic role of plasma mitotane levels pharmacokinetics and free or bound to lipoprotein fraction measurements during six consecutive months.
Article Synopsis
- Nintedanib is a drug being tested for effectiveness against advanced thyroid cancers, specifically radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC), in a phase II clinical trial (EORTC-1209).
- The study compared nintedanib with a placebo for its effects on progression-free survival (PFS) among patients, showing a median PFS of 3.7 months for nintedanib vs. 2.9 months for placebo in the RAIR DTC cohort, although no objective responses were noted in either group.
- Adverse effects were more common in the nintedanib group, with about
Article Synopsis
- The VERIFY study investigated the effectiveness of vandetanib in patients with advanced differentiated thyroid cancer that did not respond to radioiodine therapy, focusing on its safety and efficacy compared to a placebo in a randomized, double-blind phase III trial.
- The trial involved 235 patients, divided equally to receive either vandetanib or a placebo, with the main goal of assessing progression-free survival (PFS), which was found to be 10.0 months for the vandetanib group versus 5.7 months for the placebo group.
- Despite showing a longer PFS, the study did not find a significant overall survival (OS) benefit, and patients receiving vandetanib experienced more severe adverse events and deaths compared to those
Langerhans cell histiocytosis (LCH) may present as unifocal disease of the suprasellar region, with symptoms and signs of hypopituitarism, arginine vasopressin deficiency (AVP-D), and weight gain. Transcranial biopsy is necessary to define diagnosis and guide treatment decisions, but it is associated with significant morbidity. We describe a patient with Hashimoto thyroiditis and a single hypothalamic mass in whom LCH diagnosis was made by thyroid fine-needle aspiration cytology (FNAC) performed despite nonspecific findings in thyroid imaging, on the basis of a slightly elevated [18F]-fluorodeoxyglucose (FDG) avidity on PET/CT and volume increase during follow-up.
View Article and Find Full Text PDF